Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi is conducting a Phase 3 clinical study titled Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis. The study aims to evaluate the annualized relapse rate (ARR) of frexalimab compared to teriflunomide in adults with relapsing multiple sclerosis, highlighting its potential significance in improving treatment outcomes for this condition.
The study tests two interventions: Frexalimab, an experimental drug administered via infusion, and Teriflunomide, an active comparator given as an oral tablet. Both are intended to manage relapsing forms of multiple sclerosis, with frexalimab potentially offering a new treatment option.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, aiming to determine the efficacy and safety of the interventions.
The study began on November 9, 2023, with an estimated primary completion date in 2025. The latest update was submitted on August 22, 2025, indicating ongoing recruitment and study progress.
Sanofi’s study could influence its stock performance positively if results show frexalimab’s superiority or comparable efficacy to existing treatments, potentially enhancing investor confidence. The study’s outcome may also impact the competitive landscape in the multiple sclerosis treatment market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.